Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Kramer, Boris W ^a   Götz, Rudolf ^b   Rapp, Ulf R ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CASPASE 3; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; 2-(2-CHLORO-4-IODOPHENYLAMINO)-N-CYCLOPROPYLMETHOXY-3,4-DIFLUOROBENZAMIDE; BENZAMIDE DERIVATIVE; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOMA; LUNG ALVEOLUS CELL; LUNG PARENCHYMA; LUNG STRUCTURE; MITOGENESIS; MOUSE; NONHUMAN; SENSITIVITY AND SPECIFICITY; TISSUE DIFFERENTIATION; TUMOR LOCALIZATION; ADENOMA; ANIMAL; APOPTOSIS; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADENOMA; ANIMALS; APOPTOSIS; BENZAMIDES; BENZENESULFONATES; CELL DIFFERENTIATION; CELL DIVISION; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES;

EID: 3042838587     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-24     Document Type: Article

References (26)

1. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer.Science 2002, 297:63-64.
2. Shawver LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
3. Herrera R, Sebolt-Leopold JS: Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002, 8:S27-31.
4. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17:1263-1293.
5. Kerkhoff E, Rapp UR: The Ras-Raf relationship: an unfinished puzzle. Adv Enzyme Regul 2001, 41:261-267.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
7. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219-225.
8. Allen LF, Sebolt-Leopold J, Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003, 30:105-116.
9. Rapp UR, Fensterle J, Albert S, Gotz R: Raf kinases in lung tumor development. Adv Enzyme Regul 2003, 43:183-195.
10. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR: Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 2000, 11:185-190.
11. Fedorov LM, Tyrsin OY, Papadopoulos T, Camarero G, Gotz R, Rapp UR: Bcl-2 determines susceptibility to induction of lung cancer by oncogenic CRaf. Cancer Res 2002, 62:6297-6303.
12. Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Gotz R, Rapp UR: Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res 2003, 63:2268-2277.
13. Mallon R, Feldberg LR, Kim SC, Collins K, Wojciechowicz D, Hollander I, Kovacs ED, Kohler C: An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade. Anal Biochem 2001, 294:48-54.
14. Afify S, Rapp UR, Högger P: Validation of a simple chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small samples of serum. J Chromatogr B Biomed Appl, in press.
15. Cohen PT, Browne GJ, Delibegovic M, Munro S: Assay of protein phosphatase I complexes. Methods Enzymol 2003, 366:135-144.
16. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P: Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999, 6:559-568.
17. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R, Pritchard C: MEK kinase activity is not necessary for Raf-1 function. Embo J 2001, 20:1940-1951.
18. Kolch W, Heidecker G, Lloyd P, Rapp UR: Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 1991, 349:426-428.
19. Bruder JT, Heidecker G, Rapp UR: Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev 1992, 6:545-556.
20. Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P, Avruch J, Rapp UR: Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem 1994, 269:7030-7035.
21. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999, 5:810-816.
22. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS: Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003, 63:5669-5673.
23. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM: Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65:753-763.
24. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A: Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752.
25. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL, van Lohuizen M, Colomer D, Campo E: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001, 61:2409-2412.
26. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001, 84:1372-1376